CY1106513T1 - Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna - Google Patents

Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna

Info

Publication number
CY1106513T1
CY1106513T1 CY20071100518T CY071100518T CY1106513T1 CY 1106513 T1 CY1106513 T1 CY 1106513T1 CY 20071100518 T CY20071100518 T CY 20071100518T CY 071100518 T CY071100518 T CY 071100518T CY 1106513 T1 CY1106513 T1 CY 1106513T1
Authority
CY
Cyprus
Prior art keywords
dna
triple
lentinoic
hiv
recombinant cells
Prior art date
Application number
CY20071100518T
Other languages
English (en)
Inventor
Pierre Charneau
Veronique Zennou
Françoise PFLUMIO
Aude Sirven
Anne Dubart Kupperschmitt
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of CY1106513T1 publication Critical patent/CY1106513T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Abstract

Η παρούσα εφεύρεση παρέχει νουκλεϊνικά οξέα, οχήματα, ιούς και ανασυνδυασμένα κύτταρα που περιλαμβάνουν τρίκλωνες δομές, σαν αυτές που προκύπτουν από κεντρική έναρξη και περάτωση HIV-1 αντίστροφης μεταγραφής στο κέντρο των HIV-1 γραμμικών DNA γονιδιωμάτων. Αυτές οι τριπλές δομές μπορούν να δράσουν σαν cis-προσδιοριστές της πυρηνικής εισαγωγής HΙV-l DNA, επιτρέποντας μόλυνση μη-διαιρούμενων κυττάρων στόχων. Από μία πλευρά, η παρουσία της τριπλής αλληλουχίας DNA σε ένα HIV όχημα διεγείρει εντόνως την γονιδιακή μεταφορά σε αιμοποιητικά βλαστικά κύτταρα. Η εφεύρεση παρέχει επίσης μεθόδους για χρησιμοποίηση αυτών των τριπλών δομών στην παρασκευή ανασυνδυασμένων κυττάρων, όπως επίσης και σε μεθόδους χρησιμοποίησης των ανασυνδυασμένων κυττάρων ώστε να εκφράσουν πρωτεΐνες που ενδιαφέρουν και in vitro και in vivo.
CY20071100518T 1999-10-12 2007-04-13 Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna CY1106513T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15838799P 1999-10-12 1999-10-12
PCT/EP2000/010418 WO2001027304A2 (en) 1999-10-12 2000-10-10 Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna

Publications (1)

Publication Number Publication Date
CY1106513T1 true CY1106513T1 (el) 2012-01-25

Family

ID=22567880

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100518T CY1106513T1 (el) 1999-10-12 2007-04-13 Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
CY20121100075T CY1112430T1 (el) 1999-10-12 2012-01-23 Λεντινοϊικο τριπλο dνα και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dνα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100075T CY1112430T1 (el) 1999-10-12 2012-01-23 Λεντινοϊικο τριπλο dνα και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dνα

Country Status (15)

Country Link
US (7) US8093042B2 (el)
EP (2) EP1224314B1 (el)
JP (1) JP4436024B2 (el)
CN (2) CN101363029B (el)
AT (2) ATE531808T1 (el)
AU (2) AU784910B2 (el)
CA (1) CA2382832C (el)
CY (2) CY1106513T1 (el)
DE (1) DE60033045T2 (el)
DK (2) DK1224314T3 (el)
ES (2) ES2280250T3 (el)
HK (2) HK1050210B (el)
IL (3) IL148900A0 (el)
PT (2) PT1792997E (el)
WO (1) WO2001027304A2 (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
ES2447115T3 (es) 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1224314T3 (da) 1999-10-12 2007-05-21 Inst Nat Sante Rech Med Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003012054A2 (en) 2001-08-02 2003-02-13 Institut Clayton De La Recherche Methods and compositions relating to improved lentiviral vector production systems
KR20040054699A (ko) 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 제한된 발현의 렌티바이러스 벡터 및 이의 적용과 관련된방법 및 조성물
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP3293266A1 (en) 2007-05-04 2018-03-14 University Health Network Il-12 immunotherapy for cancer
EP2385107B1 (en) 2010-05-03 2016-08-24 Institut Pasteur Lentiviral vector based immunological compounds against malaria
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
WO2012069657A1 (en) 2010-11-26 2012-05-31 Institut Pasteur Identification of a human gyrovirus and applications.
ES2651922T3 (es) 2011-11-08 2018-01-30 Institut Pasteur Polipéptidos de afinidad elevada para MAST2 y usos de los mismos
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
US20150182617A1 (en) 2012-07-25 2015-07-02 Theravectys Glycoproteins for pseudotyping lentivectors
JP6691048B2 (ja) * 2013-10-24 2020-04-28 オスペダーレ サン ラファエレ エス．アール．エル 方法
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
US20180022781A1 (en) 2015-02-13 2018-01-25 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
DE102016122317A1 (de) 2015-11-24 2017-05-24 Glaxosmithkline Intellectual Property Development Limited Transientes transfektionsverfahren für retrovirale produktion
EP3211003A1 (en) 2016-02-24 2017-08-30 Institut Pasteur T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
SG11201809096VA (en) 2016-04-20 2018-11-29 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Compositions and methods for enhanced gene expression of pklr
EP3474851A4 (en) * 2016-06-22 2020-01-15 Yale University QUALITY CONTROL BASED ON A PLANT MEDICINE MECHANISM
EP3357506A1 (en) 2017-02-02 2018-08-08 Institut Pasteur Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
EP3357504A1 (en) 2017-02-02 2018-08-08 Institut Pasteur Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
US11642422B2 (en) 2017-10-16 2023-05-09 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A, M.P. Lentiviral vectors for delivery of PKLR to treat pyruvate kinase deficiency
SG11202009975TA (en) 2018-04-12 2020-11-27 Umoja Biopharma Inc Viral vectors and packaging cell lines
MA52709A (fr) 2018-05-23 2021-03-31 Modernatx Inc Administration d'adn
US20220017920A1 (en) 2018-11-21 2022-01-20 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
KR20220143634A (ko) 2019-10-16 2022-10-25 우모자 바이오파마 인코포레이티드 보편적 수용체 요법을 위한 레트로바이러스 벡터
CN117120085A (zh) 2020-07-15 2023-11-24 巴斯德研究所 Sars-cov-2免疫原性组合物、疫苗和方法
EP4182339A1 (en) 2020-07-16 2023-05-24 Umoja Biopharma, Inc. Gated adapter targeting receptor
EP4192487A1 (en) 2020-08-07 2023-06-14 Spacecraft Seven, LLC Plakophilin-2 (pkp2) gene therapy using aav vector
EP4214223A1 (en) 2020-09-21 2023-07-26 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
EP3984548A1 (en) 2020-10-16 2022-04-20 Institut Pasteur Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host
JP2023551220A (ja) 2020-11-20 2023-12-07 ウモジャ バイオファーマ インコーポレイテッド 複数のポリヌクレオチドを送達するためのベクター系およびその使用法
JP2024509976A (ja) 2021-03-12 2024-03-05 アンスティテュ・パストゥール 抗原をｍｈｃ－ｉｉ経路にターゲティングし、宿主におけるｃｄ８＋及びｃｄ４＋ｔ細胞による防御免疫を誘導するレンチウイルスベクター
WO2023115049A1 (en) 2021-12-17 2023-06-22 Umoja Biopharma, Inc. Cytotoxic innate lymphoid cell and uses thereof
WO2023225569A1 (en) 2022-05-17 2023-11-23 Umoja Biopharma, Inc. Manufacturing viral particles
WO2023240282A1 (en) 2022-06-10 2023-12-14 Umoja Biopharma, Inc. Engineered stem cells and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) * 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
EP0885302A1 (en) * 1996-03-05 1998-12-23 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
AU7158398A (en) 1997-04-17 1998-11-11 Regents Of The University Of California, The Use of lentiviral vectors for antigen presentation in dendritic cells
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7622300B2 (en) 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
ES2447115T3 (es) 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1224314T3 (da) 1999-10-12 2007-05-21 Inst Nat Sante Rech Med Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
ATE351916T1 (de) 2007-02-15
US8512993B2 (en) 2013-08-20
US20180346928A1 (en) 2018-12-06
CY1112430T1 (el) 2015-12-09
CN1402793A (zh) 2003-03-12
JP2003511083A (ja) 2003-03-25
US20150191745A1 (en) 2015-07-09
EP1224314B1 (en) 2007-01-17
IL148900A (en) 2009-11-18
HK1109167A1 (en) 2008-05-30
EP1224314A2 (en) 2002-07-24
US9238824B2 (en) 2016-01-19
WO2001027304A2 (en) 2001-04-19
EP1792997B1 (en) 2011-11-02
US20070224679A1 (en) 2007-09-27
HK1050210A1 (en) 2003-06-13
CN101363029B (zh) 2016-01-13
DE60033045T2 (de) 2007-11-08
DK1224314T3 (da) 2007-05-21
US8093042B2 (en) 2012-01-10
HK1050210B (zh) 2007-08-24
AU784910B2 (en) 2006-07-27
US20150011006A1 (en) 2015-01-08
DE60033045D1 (de) 2007-03-08
ES2280250T3 (es) 2007-09-16
IL198076A (en) 2011-12-29
US10407695B2 (en) 2019-09-10
CN100425702C (zh) 2008-10-15
CA2382832C (en) 2012-06-26
DK1792997T3 (da) 2012-01-30
WO2001027304A3 (en) 2001-11-29
US8512994B2 (en) 2013-08-20
AU7921700A (en) 2001-04-23
JP4436024B2 (ja) 2010-03-24
PT1792997E (pt) 2012-02-02
US20120122963A1 (en) 2012-05-17
CA2382832A1 (en) 2001-04-19
ES2377721T3 (es) 2012-03-30
PT1224314E (pt) 2007-04-30
EP1792997A1 (en) 2007-06-06
AU2006233199B2 (en) 2009-07-23
CN101363029A (zh) 2009-02-11
ATE531808T1 (de) 2011-11-15
AU2006233199A1 (en) 2006-11-23
US20190119699A1 (en) 2019-04-25
IL148900A0 (en) 2002-09-12
US20120122204A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
CY1106513T1 (el) Λεντινοϊικο τριπλο dna και οχηματα και ανασυνδυασμενα κυτταρα που περιεχουν λεντινοϊικο τριπλο dna
CY1117384T1 (el) Μεθοδοι για την παραγωγη παρασκευασματων ανασυνδυασμενων φορεων aav υψηλου τιτλου απαλλαγμενων απο βοηθητικους ιους
EE05138B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
EP1923467A3 (en) Adenovirus vectors for gene therapy
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
AUPN477695A0 (en) Gene therapy
DE60044754D1 (de) Trans-lentivirales Vektor System
DK0843731T3 (da) Adenovirusvektorer til genterapi
AU630861B2 (en) Recombinant hiv-2 polypeptides
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
WO2001087978A3 (en) Human abc transporter and its use
PT1140023E (pt) Formulacoes cocleares integrativas de proteina-adn e metodos de transformacao celular
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
FI924494A0 (fi) Oekad produktion av avsoendrarde proteiner i eukaryotiska rekombinantceller
FR2600079B1 (fr) Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
AU2001251410A1 (en) 12303, a novel human twik molecule and uses thereof
WO2000053789A3 (de) Retrovirale expressionsvektoren auf der basis von herv-ltr-sequenzen
WO2002088357A3 (en) 84242, 8035, 55304, 52999, and 21999, novel human proteins and methods of use thereof
TH54948B (th) ระบบการติดเชื้อด้วยกรดนิวคลีอิคที่ได้รับการส่งเสริมให้ดีขึ้น
WO2002061084A3 (en) Nt69, a nucleoside transporter family member and uses therefor